Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness

• Published in: The New England journal of medicine Vol. 379; no. 12; pp. 1118 - 1127
• Main Authors: Spyropoulos, Alex C, Ageno, Walter, Albers, Gregory W, Elliott, C. Gregory, Halperin, Jonathan L, Hiatt, William R, Maynard, Gregory A, Steg, P. Gabriel, Weitz, Jeffrey I, Suh, Eunyoung, Spiro, Theodore E, Barnathan, Elliot S, Raskob, Gary E
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 20.09.2018
• Subjects: Aftercare; Aged; Anticoagulants; Bleeding; Collaboration; Double-Blind Method; Drug Administration Schedule; Embolisms; Factor Xa Inhibitors - administration & dosage; Factor Xa Inhibitors - adverse effects; Factor Xa Inhibitors - therapeutic use; Fees & charges; Female; Health risk assessment; Heart failure; Hemorrhage - chemically induced; Hospitalization; Hospitals; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Motivation; Patient Discharge; Patients; R&D; Renal insufficiency; Research & development; Rivaroxaban - administration & dosage; Rivaroxaban - adverse effects; Rivaroxaban - therapeutic use; Stroke; Thromboembolism; Thrombosis; Treatment Outcome; Veins & arteries; Venous Thromboembolism - epidemiology; Venous Thromboembolism - mortality; Venous Thromboembolism - prevention & control; Venous Thrombosis - prevention & control; United States > US; Colorado
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa1805090

Patients discharged from the hospital carry an increased risk of venous thromboembolism after discharge. A randomized trial of rivaroxaban for 6 weeks after hospital discharge had no significant effect on the risk of venous thromboembolism as compared with placebo.